Evidence map›Paper›PMID 39058968›Full record

ArticleBlood advances2024

Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL.

Reena Pabari, Kathleen McCarten, Jamie Flerlage, Hollie Lai, Christine Mauz-Körholz, Karin Dieckmann, Monica Palese, Sue Kaste, Sharon M Castellino, Kara M Kelly and 2 more

3 registry-linked trialsAbstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00433459 phase3completednot on this map

First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents

TypeinterventionalSponsorChristine Mauz-KörholzRan2007 to 2013Enrolled2,134ConditionsLymphomaArmscyclophosphamide, dacarbazine, prednisolone, prednisone, procarbazine hydrochloride
NCT02166463 phase3active not recruitingnot on this map

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2015 to 2026Enrolled600ConditionsAnn Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin LymphomaArmsBleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
NCT02684708 phase3completednot on this map

European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

TypeinterventionalSponsorUniversity of GiessenRan2015 to 2025Enrolled2,921ConditionsClassical Hodgkin LymphomaArmscyclophosphamide, vincristine, prednisone, dacarbazine, cyclo, vcr, pred, dacarb,etop and doxo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Reena PabariDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0003-0028-9724
Kathleen McCartenDepartment of Diagnostic Imaging, Imaging and Radiation Oncology Core Rhode Island, Lincoln, RI.ORCID 0009-0002-2580-4171
Jamie FlerlageDivision of Pediatric Hematology/Oncology, Golisano Children's Hospital, Rochester, NY.ORCID 0000-0002-4182-9355
Hollie LaiDepartment of Radiology, Children's Hospital of Orange County, Orange County, CA.ORCID 0000-0001-6747-7338
Christine Mauz-KörholzDepartment of Pediatric Oncology, Justus-Liebig University, Giessen, Germany.ORCID 0000-0002-8205-8665
Karin DieckmannDepartment of Radiation Oncology, Medical University of Vienna, Vienna, Austria.
Monica PaleseDivision of Pediatric Hematology/Oncology, Golisano Children's Hospital, Rochester, NY.
Sue KasteDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.
Sharon M CastellinoDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA.
Kara M KellyDepartment of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY.
Dietrich StoevesandtDepartment of Radiology, University Hospital Halle, Halle, Germany.ORCID 0000-0001-5105-4488
Lars KurchDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.ORCID 0000-0002-3396-4880

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
IROC: Enhancing local enrolling site radiological data capture capabilities for NCTN trialsU24CA180803 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Thomas J. FitzGerald, MICHAEL V KNOPP · 2014 to 2026
$116.2M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA180803
6 · The paper itself

Abstract

abstractHodgkin lymphoma (HL) involving the central nervous system (CNS) is exceedingly rare. Information regarding the presentation, management, treatment, and outcome of patients with CNS HL is limited to case reports or small series. We describe 45 pediatric patients with 55 extra-axial CNS lesions at diagnosis with HL from a cohort of 4995 patients enrolled on Children's Oncology Group AHOD1331 and the European Network for Pediatric Hodgkin lymphoma C1 and C2 trials, with an overall incidence of 0.9%. Up to 82.2% of patients had a single CNS lesion in the thoracic, lumbar, or sacral spine. In the evaluated cohort, HL did not occur within the CNS parenchyma. Lesions extended into the extra-axial CNS space from adjacent soft tissue or bone and never directly infiltrated through the dura into the brain or spinal cord. Patients with CNS involvement had a twofold greater incidence of extranodal lesions than previously reported cohorts without CNS involvement. After 2 cycles of chemotherapy, 89.1% of CNS lesions demonstrated a complete metabolic response and >75% decrease in volume. Thirteen CNS lesions (23.6%) received irradiation; none were sites of disease relapse. Relapse occurred at the site of 2 lesions involving the CNS, both of which had an adequate interim response to chemotherapy. In summary, we present, to our knowledge, the largest reported cohort of systemic HL involving the CNS at diagnosis, demonstrating that these lesions originate from surrounding tissues, extend into the extra-axial CNS space, and respond similarly to other nodal and extranodal disease. The trials were registered at www.clinicaltrials.gov as #NCT02166463, #NCT00433459, and #NCT02684708.

Indexed as

Hodgkin DiseaseAdolescentCentral Nervous System NeoplasmsChildChild, PreschoolCohort StudiesFemaleHumansMaleTreatment Outcome

Identifiers

PMID39058968
PMCPMC11416590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.